1[1]Williams DO, Holubkov R, Yeh W, et al. Pereutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation, 2000, 102:2945-2951.
2[2]Mehran R, Dangas G, Abizaid AS, et al. Angiographic pattems of instent restenosis: classification and implacation for long-term outcome.Circulation, 1999,100:1872-1878.
3[3]Mehran R, Dangas G, Mintz GS, et al. In-stent restenosis: the great equalizer-disappointing clinical outcomes with all interventional strategies. J Am Coll Cardiol, 1999,33(suppl A):66A.
4[4]Hoffman R, Mintz GS, Dussaillant GR, et al. Pattems and mechanisms of in-stent restenosis: serial intravascular ultrasound study.Circulation, 1996,94:1247-1254.
5[5]Gregory BM, Huie P, Billingham ME , et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: its effect on cellular,growth factor, and cytokine response in injured vessels. Transplantation, 1993,55:1409-1418.
6[6]Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation, 1999, 99: 2164-2170.
7[7]Carter A J, Kopia G, Llanos G, et al. Stent based sirolimus delivery reduces neointimal proliferation in a porcine coronary model of restenosis. J Am Coll Cardiol, 2000,35(suppl):13.
8[8]Gregory CR, Katznelson S, Griffey SM, et al. Fluvastatin in combination with rad significantly reduce graft vascular disease in rat cardiac allografts. Transplantation, 2001,72:989-993.
9[9]Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature, 1979,277:665-667.
10[10]Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 1997,96:636-645.
